Primary Tumor Standardized Uptake Value (SUVmax) Measured on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is of Prognostic Value for Survival.

Slides:

Advertisements

Similar presentations

Comparison of Endobronchial Ultrasound and/or Endoesophageal Ultrasound with Transcervical Extended Mediastinal Lymphadenectomy for Staging and Restaging.

Advertisements

Evaluation of 18F-FDG PET-CT for Differentiation of Pulmonary Pathology in an Approach of Outpatient Fast Track Assessment Tjeerd S. Aukema, MD, Renato.

Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

PUBLISH ONLY Journal of Thoracic Oncology

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Masatsugu Hamaji, MD, Syed Osman Ali, MD, Bryan M. Burt, MD

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer Ernest Nadal,

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation Andrea L.H. Arnett, MD, PhD, Kenneth.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer:

Comparison of Endobronchial Ultrasound and/or Endoesophageal Ultrasound with Transcervical Extended Mediastinal Lymphadenectomy for Staging and Restaging.

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis Ping Zhan, MD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Frank Detterbeck, MD Journal of Thoracic Oncology

The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials Wei-An Song, MD,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer Stephen A. Barnett, MBBS, Robert.

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

PUBLISH ONLY Journal of Thoracic Oncology

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage Sara de Cabanyes Candela, MD, Frank.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of.

Marianna Koczywas, MD, Mihaela C. Cristea, MD

Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J

False-Positive FDG-PET and Bronchial Anthracofibrosis

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Prognostic Role of Positron Emission Tomography and High-Resolution Computed Tomography in Clinical Stage IA Lung Adenocarcinoma Hirofumi Uehara, MD,

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Mark A. Socinski, MD Journal of Thoracic Oncology

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Primary Tumor Standardized Uptake Value Measured on Fluorodeoxyglucose Positron Emission Tomography Is of Prognostic Value for Survival in Non-small Cell.

Presentation transcript:

Primary Tumor Standardized Uptake Value (SUVmax) Measured on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is of Prognostic Value for Survival in Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta- Analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project Thierry Berghmans, MD, Michèle Dusart, MD, Marianne Paesmans, MSc, Claude Hossein-Foucher, MD, Irene Buvat, PhD, Catherine Castaigne, MD, Arnaud Scherpereel, MD, PhD, Céline Mascaux, MD, Michel Moreau, MD, Martine Roelandts, MD, Stéphane Alard, MD, Anne-Pascale Meert, MD, PhD, Edward F. Patz, MD, Jean-Jacques Lafitte, MD, PhD, Jean-Paul Sculier, MD, PhD Journal of Thoracic Oncology Volume 3, Issue 1, Pages 6-12 (January 2008) DOI: 10.1097/JTO.0b013e31815e6d6b Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Graphical representation of the prognostic role of primary tumor SUV on survival in lung cancer. HR and 95% confidence interval (CI) for survival comparison in studies evaluating primary tumor SUV in lung cancer. HR >1 implied a survival benefit for reduced primary tumor SUVmax. The square size is proportional to the number of patients included in the study. The center of the diamond-shaped lozenge at the bottom of the figure gives the combined HR of the meta-analysis and its extremities the 95% CI HR = 2.27; 95% CI 1.70–3.02 (random-effect model). Total number of patients: 1474. SUV = standardized uptake value. Journal of Thoracic Oncology 2008 3, 6-12DOI: (10.1097/JTO.0b013e31815e6d6b) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions